ALLONGE TO 4% CONVERTIBLE SENIOR NOTENovavax Inc • September 14th, 2001 • Biological products, (no disgnostic substances)
THIS ALLONGE TO 4% CONVERTIBLE SENIOR NOTE (the “Allonge”), is made September 7, 2001, between King Pharmaceuticals, Inc. (“Payee”) and Novavax, Inc. (“Company”).
FIRST AMENDMENT TO INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • September 14th, 2001 • Novavax Inc • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO INVESTOR RIGHTS AGREEMENT (this “Amendment”) is entered into as of September 7, 2001, by and between KING PHARMACEUTICALS, INC., a Tennessee corporation (“King”), and NOVAVAX, INC., a Delaware corporation (the “Company”).
SEPTEMBER 2001 NOTE PURCHASE AGREEMENT by and between NOVAVAX, INC. and KING PHARMACEUTICALS, INC. Dated as of September 7, 2001September 2001 Note Purchase Agreement • September 14th, 2001 • Novavax Inc • Biological products, (no disgnostic substances) • Delaware
